Ichor Portfolio Company, Antoxerene, Closes $10MM Deal with Juvenescence

Posted Posted in Antoxerene, FoxBio, Ichor

Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity financing and drug development expertise.